Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/6988
Title: Expression of miR-31 in saliva-liquid biopsy in patients with oral squamous cell carcinoma
Authors: Kumari, Parma
Syed, Sofia A.
Wahid, Mohsin
Qureshi, Muhammad A.
Kumar, Rajesh
Keywords: Circulating microRNA
miR-31
Saliva
Oral squamous cell carcinoma
Biomarkers
Issue Date: 2021
Publisher: Journal of Taibah University Medical Sciences
Series/Report no.: Original Article;733-739
Abstract: Objectives: Oral squamous cell carcinoma (OSCC) is a commonly reported cancer in men and is second only to breast cancer in women in Pakistan.. Investigations for identifying biomarkers of OSCC are essential for diagnostic, therapeutic, or prognostic significance. This study aims to examine the miR-31 expression in the pre- and post-operative OSCC patients and correlate this expression with clinicopathological characteristics. Methods: Patients with histopathologically confirmed OSCC who had undergone surgical resections of tumours were recruited. A total of 40 saliva samples (pre- and post-operative) were collected from 19 patients and two healthy individuals. Levels of salivary miR-31 expressions were examined through quantitative reverse transcription polymerase chain reaction. Results: The salivary miR-31 expression was significantly higher in the preoperative patients than in postoperative patients (p < 0.001). However, no significant correlation had been found between the salivary miR-31 expression and clinicopathological characteristics (p > 0.05). Conclusion: Our data suggest that miR-31 can be used as an adjunct non-invasive marker to monitor surgery outcomes during postoperative follow-up in patients with OSCC.
URI: http://localhost:8080/xmlui/handle/123456789/6988
ISSN: 1658-3612
Appears in Collections:Vol 16 No 5 (2021)

Files in This Item:
File Description SizeFormat 
733-739.pdf733-7391.15 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.